Statins and the acute-phase response.

C-reactive protein is the classic acute-phase reactant. During severe infection or inflammation, blood concentrations of C-reactive protein may increase by a factor of 500 or more. Although most ot...

[1]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[2]  I. Kushner.  C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging. , 2001, Cleveland Clinic journal of medicine.

[3]  S. Grundy,et al.  Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.

[4]  J. Pugin,et al.  Normal responses to injury prevent systemic inflammation and can be immunosuppressive. , 2001, American journal of respiratory and critical care medicine.

[5]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[6]  Y. Chao,et al.  Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[7]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[8]  H Jick,et al.  HMG-CoA reductase inhibitors and the risk of fractures. , 2000, JAMA.

[9]  K. Feingold,et al.  Infection and inflammation-induced proatherogenic changes of lipoproteins. , 2000, The Journal of infectious diseases.

[10]  H. Drexler,et al.  Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. , 2000, Circulation.

[11]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[12]  W. Ricart,et al.  Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness , 1999, Diabetologia.

[13]  W. Koenig.  Fibrinogen and coronary risk , 1999, Current cardiology reports.

[14]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[15]  H. Tilg,et al.  IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. , 1997, Immunology today.